Posts filtered by tags: Joshua Krieger[x]


 

Private and Social Returns to R&D: Drug Development and Demographics

Research and development (R&D) by pharmaceutical firms focuses disproportionately on medical conditions afflicting the elderly. The proportion of R&D spending targeting older age groups is increasing over time. Even though these investments in R&D prolong life expectancy and improve quality of life, they have little effect on measured productivity and output growth. [Author: by Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou, and Joshua Krieger]
Tags: College, Dimitris Papanikolaou, Joshua Krieger, by Efraim Benmelech, Janice Eberly, and Joshua Krieger


Find and Replace: R&D Investment Following the Erosion of Existing Products

This study by Joshua Krieger and colleagues sheds light on how product outcomes shape the direction of innovation and markets for technology. [Author: by Joshua Krieger, Xuelin Li, and Richard T. Thakor]
Tags: College, by Joshua Krieger, Joshua Krieger, Xuelin Li, and Richard T. Thakor, Joshua Krieger Xuelin Li, Richard T Thakor


In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?

Pharmaceutical companies are criticized for not producing more breakthrough drugs. But new research by Joshua Krieger and colleagues shows that, given a financial windfall, drug giants turn on the innovation. [Author: by Rachel Layne]
Tags: College, by Rachel Layne, Rachel Layne, Joshua Krieger